These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 16358829)

  • 21. Evaluation of a two-dose measles, mumps, and rubella vaccination schedule in a cohort of college athletes.
    Coté TR; Sivertson D; Horan JM; Lindegren ML; Dwyer DM
    Public Health Rep; 1993; 108(4):431-5. PubMed ID: 8341775
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Seroepidemiological study of measles after the 1992 nationwide MMR revaccination program in Taiwan.
    Chiu HH; Lee CY; Chih TW; Lee PI; Chang LY; Lin YJ; Hsu CM; Huang LM
    J Med Virol; 1997 Jan; 51(1):32-5. PubMed ID: 8986946
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Serosurvey of measles, mumps and rubella antibodies in Saudi children.
    Al-Mazrou YY; Khalil MK; Tischer A; Al-Jeffri MH; Al-Ghamdi YS; Bakhsh MM; Mishkas AA; Elgizouli SA
    Saudi Med J; 2005 Oct; 26(10):1551-4. PubMed ID: 16228054
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Serological survey of measles immunity in the Czech Republic, 2013.
    Tomášková H; Zelená H; Kloudová A; Tomášek I
    Cent Eur J Public Health; 2018 Mar; 26(1):22-27. PubMed ID: 29684293
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Measles vaccination coverage and seroprevalence of anti-measles antibody in south-east Islamic Republic of Iran.
    Izadi S; Mokhtari-Azad T; Zahraei SM
    East Mediterr Health J; 2015 Sep; 21(6):396-402. PubMed ID: 26369998
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Use of combination measles, mumps, rubella, and varicella vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Marin M; Broder KR; Temte JL; Snider DE; Seward JF;
    MMWR Recomm Rep; 2010 May; 59(RR-3):1-12. PubMed ID: 20448530
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Humoral and cell-mediated immune responses to an early 2-dose measles vaccination regimen in the United States.
    Gans HA; Yasukawa LL; Alderson A; Rinki M; DeHovitz R; Beeler J; Audet S; Maldonado Y; Arvin AM
    J Infect Dis; 2004 Jul; 190(1):83-90. PubMed ID: 15195246
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunogenicity and efficacy of Hoshino strain of mumps vaccine in Iran; two years study.
    Avijgan M; Hafizi M; Moghni M; Kheiri S; Esteghamati A; Sarikhani S
    East Afr J Public Health; 2011 Jun; 8(2):88-91. PubMed ID: 22066292
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Measles, mumps and rubella: vaccination rate and seroprevalence in 8th grade students of 8 different sites in Switzerland 1995/96].
    Stohrer-Draxl P; Amstad H; Grize L; Gassner M; Takken-Sahli K; Bourquin C; Braun-Fahrländer C
    Praxis (Bern 1994); 1999 Jun; 88(24):1069-77. PubMed ID: 10420798
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Development of a robust and standardized immunoserological assay for detection of anti-measles IgG antibodies in human sera.
    Böröcz K; Csizmadia Z; Markovics Á; Mészáros V; Farkas K; Telek V; Varga V; Maloba GO; Bodó K; Najbauer J; Berki T; Németh P
    J Immunol Methods; 2019 Jan; 464():1-8. PubMed ID: 30056035
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of vaccination with measles-mumps-rubella vaccine at 9, 12, and 15 months of age.
    Redd SC; King GE; Heath JL; Forghani B; Bellini WJ; Markowitz LE
    J Infect Dis; 2004 May; 189 Suppl 1():S116-22. PubMed ID: 15106100
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Two-year antibody persistence in children vaccinated at 12-15 months with a measles-mumps-rubella virus vaccine without human serum albumin.
    Berry AA; Abu-Elyazeed R; Diaz-Perez C; Mufson MA; Harrison CJ; Leonardi M; Twiggs JD; Peltier C; Grogg S; Carbayo A; Shapiro S; Povey M; Baccarini C; Innis BL; Henry O
    Hum Vaccin Immunother; 2017 Jul; 13(7):1516-1522. PubMed ID: 28481690
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Seroconversion after measles vaccination at nine and fifteen months of age.
    Işik N; Uzel N; Gökçay G; Kiliç A; Yilmaz G; Sadikoğlu B; Diri S
    Pediatr Infect Dis J; 2003 Aug; 22(8):691-5. PubMed ID: 12913768
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Response to third rubella vaccine dose.
    Siira L; Nøkleby H; Barlinn R; Riise ØR; Aaberge IS; Dudman SG
    Hum Vaccin Immunother; 2018; 14(10):2472-2477. PubMed ID: 29771601
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prevalence of anti-rubella, anti-measles and anti-mumps IgG antibodies in neonates and pregnant women in Catalonia (Spain) in 2013: susceptibility to measles increased from 2003 to 2013.
    Plans P; de Ory F; Campins M; Álvarez E; Payà T; Guisasola E; Compte C; Vellbé K; Sánchez C; Lozano MJ; Aran I; Bonmatí A; Carreras R; Jané M; Cabero L
    Eur J Clin Microbiol Infect Dis; 2015 Jun; 34(6):1161-71. PubMed ID: 25666082
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mumps, measles and rubella vaccination in children with PFAPA syndrome.
    Kraszewska-Głomba B; Matkowska-Kocjan A; Miśkiewicz K; Szymańska-Toczek Z; Wójcik M; Banyś D; Szenborn L
    Vaccine; 2016 Nov; 34(48):5903-5906. PubMed ID: 27997341
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunogenicity and safety of a novel MMR vaccine (live, freeze-dried) containing the Edmonston-Zagreb measles strain, the Hoshino mumps strain, and the RA 27/3 rubella strain: Results of a randomized, comparative, active controlled phase III clinical trial.
    Sood A; Mitra M; Joshi HA; Nayak US; Siddaiah P; Babu TR; Mahapatro S; Sanmukhani J; Gupta G; Mittal R; Glueck R
    Hum Vaccin Immunother; 2017 Jul; 13(7):1523-1530. PubMed ID: 28362563
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Persistence of antibodies induced by measles-mumps-rubella vaccine in children in India.
    Raut SK; Kulkarni PS; Phadke MA; Jadhav SS; Kapre SV; Dhere RM; Dhorje SP; Godse SR
    Clin Vaccine Immunol; 2007 Oct; 14(10):1370-1. PubMed ID: 17699834
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Residual susceptibility to measles among young adults in Victoria, Australia following a national targeted measles-mumps-rubella vaccination campaign.
    Kelly HA; Gidding HF; Karapanagiotidis T; Leydon JA; Riddell MA
    BMC Public Health; 2007 Jun; 7():99. PubMed ID: 17555601
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Interruption of measles transmission in Gipuzkoa (Basque Country), Spain.
    Cilla G; Basterretxea M; Artieda J; Vicente D; Pérez-Trallero E
    Euro Surveill; 2004 May; 9(5):29-31. PubMed ID: 15208472
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.